AU4504000A
(en)
*
|
1993-04-27 |
2000-09-07 |
Sepracor, Inc. |
Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
|
JPH08509738A
(en)
*
|
1993-04-27 |
1996-10-15 |
セプラコー,インコーポレイテッド |
Methods and compositions for the treatment of gastric disorders using optically pure (+) pantoprazole
|
WO1994024867A1
(en)
*
|
1993-04-27 |
1994-11-10 |
Sepracor, Inc. |
Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
|
US6875872B1
(en)
|
1993-05-28 |
2005-04-05 |
Astrazeneca |
Compounds
|
SE9302396D0
(en)
*
|
1993-07-09 |
1993-07-09 |
Ab Astra |
A NOVEL COMPOUND FORM
|
TNSN95062A1
(en)
*
|
1994-05-27 |
1996-02-06 |
Astra Ab |
NEW DIALKOXY-PYRIDINYLE-BENZIMIDAZOLE DERIVATIVES
|
TNSN95063A1
(en)
*
|
1994-05-27 |
1996-02-06 |
Astra Ab |
NEW SUBSTITUTED BENZIMIDAZOLES
|
SE504459C2
(en)
*
|
1994-07-15 |
1997-02-17 |
Astra Ab |
Process for the preparation of substituted sulfoxides
|
GB9423970D0
(en)
*
|
1994-11-28 |
1995-01-11 |
Astra Ab |
Oxidation
|
GB9423968D0
(en)
*
|
1994-11-28 |
1995-01-11 |
Astra Ab |
Resolution
|
HRP960232A2
(en)
*
|
1995-07-03 |
1998-02-28 |
Astra Ab |
A process for the optical purification of compounds
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6489346B1
(en)
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
SE510666C2
(en)
*
|
1996-12-20 |
1999-06-14 |
Astra Ab |
New Crystal Modifications
|
SE510650C2
(en)
|
1997-05-30 |
1999-06-14 |
Astra Ab |
New association
|
EE04800B1
(en)
*
|
1997-12-08 |
2007-04-16 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form
|
WO1999038513A1
(en)
*
|
1998-01-30 |
1999-08-05 |
Sepracor Inc. |
R-lansoprazole compositions and methods
|
AU2481899A
(en)
*
|
1998-01-30 |
1999-08-16 |
Sepracor, Inc. |
S-lansoprazole compositions and methods
|
IL142703A
(en)
|
1998-11-10 |
2006-04-10 |
Astrazeneca Ab |
Crystalline form of omeprazole
|
SE9900274D0
(en)
|
1999-01-28 |
1999-01-28 |
Astra Ab |
New compound
|
TWI275587B
(en)
|
1999-06-17 |
2007-03-11 |
Takeda Chemical Industries Ltd |
A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
|
US6608092B1
(en)
*
|
1999-06-30 |
2003-08-19 |
Takeda Chemical Industries, Ltd. |
Crystals of benzimidazole compounds
|
US6369087B1
(en)
|
1999-08-26 |
2002-04-09 |
Robert R. Whittle |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6268385B1
(en)
|
1999-08-26 |
2001-07-31 |
Robert R. Whittle |
Dry blend pharmaceutical formulations
|
US6262085B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6262086B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6780880B1
(en)
|
1999-08-26 |
2004-08-24 |
Robert R. Whittle |
FT-Raman spectroscopic measurement
|
US6326384B1
(en)
|
1999-08-26 |
2001-12-04 |
Robert R. Whittle |
Dry blend pharmaceutical unit dosage form
|
US6316020B1
(en)
*
|
1999-08-26 |
2001-11-13 |
Robert R. Whittle |
Pharmaceutical formulations
|
US6312712B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Method of improving bioavailability
|
US6312723B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
DK1293507T3
(en)
|
2000-05-15 |
2007-12-27 |
Takeda Pharmaceutical |
Process for producing crystals
|
CA2775616C
(en)
|
2000-08-04 |
2013-09-17 |
Takeda Pharmaceutical Company Limited |
Salts of benzimidazole compound and application thereof
|
MY137726A
(en)
|
2000-11-22 |
2009-03-31 |
Nycomed Gmbh |
Freeze-dried pantoprazole preparation and pantoprazole injection
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
TW200410955A
(en)
*
|
2002-07-29 |
2004-07-01 |
Altana Pharma Ag |
Novel salt of (S)-PANTOPRAZOLE
|
EP2596791B1
(en)
|
2002-10-16 |
2015-04-01 |
Takeda Pharmaceutical Company Limited |
Stable solid preparations
|
DE10254167A1
(en)
|
2002-11-20 |
2004-06-09 |
Icon Genetics Ag |
Process for the control of cellular processes in plants
|
PT1578742E
(en)
|
2002-12-06 |
2013-01-24 |
Nycomed Gmbh |
Process for preparing optically pure active compounds
|
CA2507889C
(en)
|
2002-12-06 |
2012-02-07 |
Altana Pharma Ag |
Process for preparing (s)-pantoprazole
|
WO2004056804A2
(en)
|
2002-12-19 |
2004-07-08 |
Teva Pharmaceutical Industries Ltd. |
Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
|
ES2245277T1
(en)
*
|
2003-03-12 |
2006-01-01 |
Teva Pharmaceutical Industries Limited |
SOLIDOS CRYSTALS AND AMORPHES OF PANTOPRAZOL AND PROCEDURES FOR THEIR PREPARATION.
|
CN1842525A
(en)
|
2003-05-05 |
2006-10-04 |
兰贝克赛实验室有限公司 |
Barium salt of benzimidazole derivative
|
PE20050150A1
(en)
*
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT
|
EP1615913A2
(en)
|
2003-06-10 |
2006-01-18 |
Teva Pharmaceutical Industries Limited |
Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
WO2005012289A1
(en)
*
|
2003-07-17 |
2005-02-10 |
Altana Pharma Ag |
Novel salt of (r) - pantoprazole
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
SE0400410D0
(en)
|
2004-02-20 |
2004-02-20 |
Astrazeneca Ab |
New compounds
|
EP1740571B1
(en)
|
2004-04-28 |
2009-07-29 |
Hetero Drugs Limited |
A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
ES2338556T3
(en)
|
2004-05-28 |
2010-05-10 |
Hetero Drugs Limited |
NOVEDOUS STEREOSELECTIVE SYNTHESIS OF SULFOXIDES OF BENZIMIDAZOL.
|
AU2005264864B2
(en)
|
2004-06-16 |
2011-08-11 |
Takeda Pharmaceutical Company Limited |
Multiple PPI dosage form
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
ES2259269B1
(en)
|
2005-03-03 |
2007-11-01 |
Esteve Quimica, S.A. |
PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE.
|
JP4837722B2
(en)
|
2005-03-25 |
2011-12-14 |
リブゾン ファーマシューティカル グループ インク. |
Substituted sulfoxide compounds, methods for their preparation, and methods for their use
|
US7601737B2
(en)
|
2005-07-26 |
2009-10-13 |
Nycomed Gmbh |
Isotopically substituted proton pump inhibitors
|
US7576219B2
(en)
|
2005-10-26 |
2009-08-18 |
Hanmi Pharm. Co., Ltd |
Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
|
EP1801110A1
(en)
|
2005-12-22 |
2007-06-27 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Esomeprazole arginine salt
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
ES2325336T3
(en)
|
2005-12-28 |
2009-09-01 |
Union Quimico-Farmaceutica, S.A. |
PROCEDURE FOR THE PREPARATION OF OMEPRAZOL'S ENANTIOM (S).
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US7786309B2
(en)
|
2006-06-09 |
2010-08-31 |
Apotex Pharmachem Inc. |
Process for the preparation of esomeprazole and salts thereof
|
MY148301A
(en)
|
2006-07-05 |
2013-03-29 |
Lupin Ltd |
Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds
|
EP2068841B1
(en)
|
2006-10-05 |
2018-09-26 |
Santarus, Inc. |
Novel formulations of proton pump inhibitors and methods of using these formulations
|
AU2007317561A1
(en)
|
2006-10-27 |
2008-05-15 |
The Curators Of The University Of Missouri |
Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
|
EP1947099A1
(en)
|
2007-01-18 |
2008-07-23 |
LEK Pharmaceuticals D.D. |
Process for solvent removal from omeprazole salts
|
ES2532854T3
(en)
|
2007-02-21 |
2015-04-01 |
Cipla Limited |
Process for the preparation of magnesium esomeprazole dihydrate
|
ATE533758T1
(en)
*
|
2007-09-25 |
2011-12-15 |
Hetero Drugs Ltd |
METHOD FOR PRODUCING ENANTIOMER PURE ESOMEPRAZOLE
|
WO2009049160A1
(en)
|
2007-10-12 |
2009-04-16 |
Takeda Pharmaceuticals North America |
Methods of treating gastrointestinal disorders independent of the intake of food
|
CA2671369C
(en)
|
2008-03-10 |
2011-05-10 |
Takeda Pharmaceutical Company Limited |
Crystal of benzimidazole compound
|
EP2143722A1
(en)
|
2008-07-09 |
2010-01-13 |
Lek Pharmaceuticals D.D. |
Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
|
CA2736547C
(en)
|
2008-09-09 |
2016-11-01 |
Pozen Inc. |
Method for delivering a pharmaceutical composition to patient in need thereof
|
EP2264024A1
(en)
|
2008-10-14 |
2010-12-22 |
LEK Pharmaceuticals d.d. |
Process for the preparation of enantiomerically enriched proton pump inhibitors
|
US8354541B2
(en)
|
2008-11-18 |
2013-01-15 |
Hetero Research Foundation |
Optical purification of esomeprazole
|
WO2011004387A2
(en)
|
2009-06-18 |
2011-01-13 |
Matrix Laboratories Ltd |
Process for the preparation of dexlansoprazole polymorphic forms
|
EP2445499A4
(en)
|
2009-06-25 |
2013-02-27 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an nsaid-associated ulcer
|
US8748619B2
(en)
|
2009-11-12 |
2014-06-10 |
Hetero Research Foundation |
Process for the resolution of omeprazole
|
US9233103B2
(en)
|
2011-03-25 |
2016-01-12 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
|
CN104519888A
(en)
|
2011-12-28 |
2015-04-15 |
波曾公司 |
Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
RU2726320C1
(en)
*
|
2020-02-09 |
2020-07-13 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) |
Method for determining omeprazole impurity components
|
WO2024075017A1
(en)
|
2022-10-04 |
2024-04-11 |
Zabirnyk Arsenii |
Inhibition of aortic valve calcification
|